FBXO22是复发性软骨肉瘤的一个潜在治疗靶点。
FBXO22 is a potential therapeutic target for recurrent chondrosarcoma.
作者信息
Xin Baoquan, Chen Hui, Zhu Zhi, Guan Qiujing, Bai Guangjian, Yang Cheng, Zou WeiWei, Gao Xin, Li Lei, Liu Tielong
机构信息
School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200003, China.
Department of Orthopaedic Oncology, Changzheng Hospital, Navy Medical University, No. 415 Fengyang Road, Shanghai, 200003, China.
出版信息
J Bone Oncol. 2024 May 1;46:100605. doi: 10.1016/j.jbo.2024.100605. eCollection 2024 Jun.
Chondrosarcoma (CHS) is a malignant bone tumor with insensitivity to both radiotherapy and chemotherapy, and a high recurrence rate. However, the latent mechanism of recurrent CHS (Re-CHS) remains elusive. Here, we discovered that FBXO22 was highly expressed in clinical samples of Re-CHS. FBXO22 played a significant role in various cancers. However, the role of FBXO22 in Re-CHS remained unclear. Our research demonstrated that suppressing FBXO22 abated the proliferation and migration of CHS cells and facilitated their apoptosis. In addition, suppressing FBXO22 raised the expression of PD-L1 in Re-CHS. All these findings provide new evidence for using FBXO22 and PD-L1 as combined targets to prevent and treat Re-CHS, which may prove to be a novel strategy for immunotherapy of CHS, especially Re-CHS.
软骨肉瘤（CHS）是一种对放疗和化疗均不敏感且复发率高的恶性骨肿瘤。然而，复发性软骨肉瘤（Re-CHS）的潜在机制仍不清楚。在此，我们发现FBXO22在Re-CHS的临床样本中高表达。FBXO22在多种癌症中发挥重要作用。然而，FBXO22在Re-CHS中的作用仍不明确。我们的研究表明，抑制FBXO22可减弱CHS细胞的增殖和迁移并促进其凋亡。此外，抑制FBXO22可提高Re-CHS中PD-L1的表达。所有这些发现为将FBXO22和PD-L1作为联合靶点预防和治疗Re-CHS提供了新证据，这可能是CHS尤其是Re-CHS免疫治疗的一种新策略。
Zotero 插件